GAD-7 Anxiety Severity

Abstract

The Generalized Anxiety Disorder 7-item scale (GAD-7) is a concise, highly efficient self-report instrument primarily developed to screen for and accurately assess the severity of Generalized Anxiety Disorder (GAD). The scale consists of seven core items that capture key anxiety symptoms experienced over the preceding two weeks, utilizing a 4-point frequency response format. Scores range from 0 to 21, with validated clinical cut points established at 5, 10, and 15, corresponding to mild, moderate, and severe levels of anxiety severity, respectively. Although its primary focus is GAD, the GAD-7 demonstrates robust operating characteristics for detecting other common anxiety disorders, making it an indispensable tool across diverse clinical and primary care settings.

Keywords

GAD-7, Generalized Anxiety Disorder, anxiety severity, screening tool, self-report, primary care, psychometrics, Patient Health Questionnaire (PHQ).

Authors

Robert L. Spitzer, Kurt Kroenke, Janet B.W. Williams, Bernd Löwe.

Purpose

The central purpose of the GAD-7 is dual: to function as an efficient and rapid screening measure for Generalized Anxiety Disorder (GAD) and to provide a quantifiable assessment of the current severity of anxiety symptoms experienced by the individual. The scale was specifically engineered for rapid implementation and validated assessment within high-volume clinical environments, such as primary care settings, where anxiety disorders are often prevalent but undiagnosed.

Beyond its diagnostic screening function, the GAD-7 is widely used as a general metric of overall anxiety symptom burden. Clinical guidelines suggest that a total score of 10 or greater necessitates further comprehensive clinical evaluation to determine the presence of an anxiety disorder. Furthermore, the instrument serves a crucial role in monitoring the efficacy of therapeutic interventions by systematically tracking changes in the patient’s anxiety severity scores across the duration of treatment.

Construct

The GAD-7 is designed to measure the core symptomatic features that define Generalized Anxiety Disorder (GAD), with particular emphasis on chronic, uncontrollable worry and its subsequent physical and psychological manifestations. The seven items were carefully selected to reflect the essential diagnostic criteria for GAD, assessing the frequency with which an individual experiences these core symptoms over a two-week period.

The construct comprehensively covers several dimensions of anxiety, including emotional components (e.g., feeling nervous or on edge), cognitive components (e.g., inability to control worrying), and somatic components (e.g., trouble relaxing, restlessness, and irritability). By summing the weighted frequency of these symptoms, the scale provides a reliable, continuous measure of overall anxiety severity.

Validity

The validity of the GAD-7 is robustly supported by extensive validation studies, which consistently benchmarked the scale’s results against detailed structured diagnostic interviews. The instrument demonstrates strong concurrent validity, exhibiting high sensitivity and specificity crucial for accurately identifying cases of Generalized Anxiety Disorder (GAD) within diverse populations, particularly in primary care settings.

Importantly, the scale’s utility extends beyond GAD; it possesses moderately good operational characteristics for screening for other prevalent anxiety conditions, including Panic Disorder, Social Anxiety Disorder, and Post-Traumatic Stress Disorder (PTSD). The established scoring framework, utilizing cut points of 5, 10, and 15, successfully establishes clear differentiation between mild, moderate, and severe anxiety levels, confirming its reliability as a measure of symptom severity.

Reliability

The GAD-7 is highly regarded in clinical psychometrics for its strong internal consistency. This consistency confirms that the seven individual items reliably measure the singular, unified construct of anxiety severity, ensuring that all scale components are highly intercorrelated and consistently assess the same underlying psychological dimension.

Furthermore, the scale has demonstrated acceptable test-retest reliability. This indicates that scores remain stable over short intervals when the patient’s underlying clinical status is presumed unchanged. This stability, coupled with the GAD-7’s proven sensitivity to genuine clinical change, establishes it as a highly reliable instrument suitable for both initial diagnostic screening and effective longitudinal monitoring of treatment outcomes.

Factor Analysis

Factor analysis studies performed during the development and validation of the GAD-7 consistently support a clear unidimensional factor structure. This critical psychometric finding confirms that all seven items load onto a single, dominant factor, which represents the overall severity of generalized anxiety symptoms. This simple, singular structure significantly enhances the scale’s clinical utility, ensuring it remains brief, easily administered, and highly interpretable for clinicians.

Instrument

Test Type: Self-report questionnaire / Screening and Severity Measure

Format: 7-item Likert scale. Items are scored on a 4-point frequency scale: 0 (“not at all”), 1 (“several days”), 2 (“more than half the days”), and 3 (“nearly every day”). The total cumulative score ranges from 0 to 21. Scores of 5, 10, and 15 serve as the established cut points for classifying mild, moderate, and severe anxiety, respectively.

Language Available: English (Numerous rigorous and validated translations are available globally, enhancing cross-cultural utility).

Population Group: Adults and Adolescents in primary care, clinical, and community settings.

Age Group: Typically 18+ (though its use is common and validated in older adolescent populations).

Population Details: Originally validated among primary care patients and obstetrics-gynecologic patients, the GAD-7 is now routinely employed across a broad spectrum of medical, mental health, and general community populations globally.

Test Methodology: Respondents evaluate how frequently they have been troubled by each of the seven listed anxiety problems over the last two weeks. The resultant frequency responses are summed to produce a quantifiable total score reflecting anxiety severity. A score equal to or exceeding 10 is the recommended clinical threshold for prompting further diagnostic evaluation for GAD or any other anxiety disorder.

Keywords

Psychological assessment, GAD, mental health screening, anxiety symptoms, Patient Health Questionnaire (PHQ), panic disorder, social anxiety disorder, PTSD, unidimensional structure.

Authors

Author ORCID Identifier: N/A (Information not provided in source documents)

Affiliation Email addresses: N/A (Information not provided in source documents)

Correspondence Address: N/A (Refer to primary publications by Spitzer RL, Kroenke K, and Williams JBW for correspondence details, notably the 2006 validation study in Arch Intern Med)

Permissions & Fee and Test Year

The GAD-7 is an integral component of the Patient Health Questionnaire (PHQ) series, developed by Drs. Spitzer, Kroenke, and Williams. It is generally available free of charge for clinical application, educational purposes, and non-commercial research use. The seminal validation study that established the GAD-7’s psychometric properties was published in 2006.

Test Year: 2006 (Key Validation Publication)

The original PDF containing the GAD-7 and PHQ-9 can be downloaded here: http://www.goodmedicine.org.uk/files/assessment‚%20phq9‚%20gad7‚%20etc.pdf

Reference’s

• Spitzer RL‚ Kroenke K‚ Williams JBW‚ for the Patient Health Questionnaire Primary Care Study Group. Validation and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study. JAMA 1999;282:1737-1744.
• Spitzer RL‚ Williams JBW‚ Kroenke K‚ et al. Validity and utility of the Patient Health Questionnaire in assessment of 3000 obstetrics-gynecologic patients. Am J Obstet Gynecol 2000; 183:759-769
• Spitzer RL‚ Kroenke K‚ Williams JBW‚ Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-1097.
• Kroenke K‚ Spitzer RL‚ Williams JBW. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-613.
• Kroenke K‚ Spitzer RL‚ Williams JBW. The PHQ-15: Validity of a new measure for evaluating somatic symptom severity. Psychosom Med 2002;64:258-266.
• Kroenke K‚ Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatric Annals 2002;32:509-521. [also includes validation data on PHQ-8]
• Kroenke K‚ Spitzer RL‚ Williams JBW. The Patient Health Questionnaire-2 : validity of a two-item depression screener. Med Care 2003; 41:1284-1292.
• Kroenke K‚ Spitzer RL‚ Williams JBW‚ Monahan PO‚ Löwe B. Anxiety disorders in primary care: prevalence‚ impairment‚ comorbidity‚ and detection. Ann Intern Med 2007 (in press). [also includes additional validation data on GAD-7 and GAD-2]
• Kroenke K‚ Spitzer RL‚ Williams JBW‚ Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Under review.
• Löwe B‚ Kroenke K‚ Herzog W‚ Gräfe K. Measuring depression outcome with a short self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). J Affective Disorders 2004;78:131-140.
• Löwe B‚ Unutzer J‚ Callahan CM‚ Perkins AJ‚ Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care 2004;42:1194-1201.

Items of the GAD-7 Anxiety Severity

IMPORTANT: The following scale items must be preserved in their original language and must not be changed in any way.